Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

NCT03744468 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
HNSCC for Phase 2 Dose Expansion
NSCLC for Phase 2 Dose Expansion

Interventions

DRUG: Surzebiclimab
DRUG: Tislelizumab
DRUG: Alcestobart

Sponsor

BeiGene